Hepatocyte growth factor (HGF) exclusively stimulates the growth of endothelial cells without replication of vascular smooth muscle cells, and acts as a survival factor against endothelial cell death. Recently, a novel therapeutic strategy for ischemic diseases using angiogenic growth factors to expedite and/or augment collateral artery development has been proposed. We have previously reported that intraarterial administration of recombinant HGF induced angiogenesis in a rabbit hindlimb ischemia model. In this study, we examined the feasibility of gene therapy using HGF to treat peripheral arterial disease rather than recombinant therapy, due to its disadvantages. Initially, we examined the transfection of 'naked' human HGF plasmid into a rat hindlimb ischemia model. Intramuscular injection of human HGF plasmid resulted in a significant increase in blood flow as assessed by laser Doppler imaging, accompanied by the detection of human HGF protein. A significant increase in capillary density was found in rats transfected with human HGF as compared with control vector, in a dose-dependent manner (P Ͻ 0.01). Importantly, at 5 weeks after transfection, the degree of angiogenesis induced by transfection of HGF plasmid was significantly greater than that caused by
Introduction
Critical limb ischemia is estimated to develop in 500 to 1000 individuals per million per year. 1 In a large proportion of these patients, the anatomical extent and the distribution of arterial occlusive disease make the patients unsuitable for operative or percutaneous revascularization. Thus, the disease frequently follows an inexorable downhill course. 2, 3 Of importance, there is no optimal medical therapy for critical limb ischemia, as the Consensus Document of the European Working Group on Critical Limb Ischemia concluded. 1 Therefore, novel a single injection of recombinant HGF. As an approach to human gene therapy, we also employed a rabbit hindlimb ischemia model as a preclinical study. Naked HGF plasmid was intramuscularly injected in the ischemic hindlimb of rabbits, to evaluate its angiogenic activity. Intramuscular injection of HGF plasmid once on day 10 after surgery produced significant augmentation of collateral vessel development on day 30 in the ischemia model, as assessed by angiography (P Ͻ 0.01). Serial angiograms revealed progressive linear extension of collateral arteries from the origin stem artery to the distal point of the reconstituted parent vessel in HGFtransfected animals. In addition, a significant increase in blood flow was assessed by a Doppler flow wire and the ratio in blood pressure of the ischemic limb to the normal limb was observed in rabbits transfected with HGF plasmid as compared with rabbits transfected with control vector (P Ͻ 0.01). Overall, intramuscular injection of naked human HGF plasmid induced therapeutic angiogenesis in rat and rabbit ischemic hindlimb models, as potential therapy for peripheral arterial disease. Gene Therapy (2001) 8, 181-189.
therapeutic modalities are needed to treat these patients. In the pathophysiology of the disease, in the presence of obstruction of a major artery, blood flow to the ischemic tissue is often dependent on collateral vessels. When spontaneous development of collateral vessels is insufficient to allow normal perfusion of the tissue at risk, ischemia occurs. Recently, the efficacy of therapeutic angiogenesis using VEGF (vascular endothelial growth factor) gene transfer has been reported in human patients with critical limb ischemia and myocardial ischemia. [4] [5] [6] Thus, the strategy for therapeutic angiogenesis using angiogenic growth factors should be considered for the treatment of patients with critical limb ischemia or myocardial infarction. Most of the studies have used VEGF, also known as vascular permeability factor, as well as a secreted endothelial-cell mitogen. The endothelial cell specificity of VEGF has been considered to be an important advantage for therapeutic angiogenesis, as endothelial cells represent the critical cellular element responsible for new vessel formation. 7, 8 From this viewpoint, hepatocyte growth factor (HGF) originally cloned as hepatocyte mitogen, 9 is also of particular interest, as HGF exclusively stimulated the growth of endothelial cells without replication of vascular smooth muscle cells (VSMC).
10-12 Indeed, we and others previously reported that HGF is a potent angiogenic growth factor which is useful for effective therapeutic angiogenesis in a rabbit ischemia model. 13, 14 Unexpectedly, the mitogenic activity of HGF is more potent than that of VEGF in human aortic endothelial cells in vitro, as well as a rabbit hindlimb ischemia model in vivo. 11, 14 Moreover, its specific receptor, c-met, has been shown to be up-regulated in ischemic tissue. 15 Therefore, we reasoned that HGF should be a potential therapeutic angiogenic growth factor, in addition to VEGF. In this study, we examined the feasibility of gene therapy using HGF to treat peripheral arterial disease rather than recombinant therapy for the following reasons: (1) It has the potential to maintain an optimally high and local concentration over time. This issue may be critical in the case of arterial gene therapy. However, in the case of therapeutic angiogenesis, it may be preferable to deliver a lower dose over a period of several days or more from an actively expressed transgene in the iliac artery, rather than a single or multiple bolus doses of recombinant protein, to avoid side-effects. (2) Regarding economics, which therapy would ultimately cost more to develop, implement, and reimburse, particularly for those indications requiring multiple or even protracted treatment, needs to be considered. (3) The feasibility of a clinical trial of recombinant protein is currently limited by the lack of approved or available quantities of human quality grade of recombinant protein, due in large part to the nearly prohibitive cost of scaling up from research grade to human quality recombinant protein. Here, we demonstrated in preclinical studies that injection of 'naked' HGF plasmid induced therapeutic angiogenesis to treat peripheral arterial disease in rat and rabbit hindlimb ischemia models, directed toward human clinical trials.
Results
Angiogenesis induced by intramuscular injection of 'naked' human HGF plasmid in rat ischemia model Initially, we measured rat endogenous HGF concentration in the hindlimb. As shown in Figure 1a , HGF concentration in the ischemic hindlimb was significantly decreased as compared with that in the non-ischemic hindlimb as control at 4 days after ischemia. Similar results have been obtained in human blood vessels of patients with peripheral arterial disease. 13 Down-regulation of the endogenous HGF system may be related to the pathogenesis of peripheral arterial disease, since HGF has shown an anti-apoptotic action on endothelial cells, in addition to its mitogenic activity. 16, 17 The decrease in local HGF production in the ischemic hindlimb might be due to transforming growth factor-␤ or hypoxia, which are strong suppressors of vascular HGF in vitro as well as in vivo. 18, 19 Given the significant decrease in endogenous HGF production in the ischemic limb, we hypothesized that transfection of human HGF vector into the isch- emic limb might result in a beneficial effect in hypoxia. Therefore, HGF plasmid was intramuscularly transfected into the ischemic hindlimb of rats in which the femoral artery was excised to induce unilateral hindlimb ischemia.
First, we transfected luciferase gene into the ischemic hindlimb, to examine the feasibility of gene transfer using naked plasmid DNA. Consistent with a previous report, 20 luciferase activity could be detected in muscle transfected with luciferase vector at 5 days after transfection (control: not detected, luciferase: 64 400 ± 12 600 RLU/g tissue, P Ͻ 0.01). Then, we measured human HGF concentration in the ischemic hindlimb transfected with human HGF or control vector. Expectedly, human immunoreactive HGF was readily detected in the hindlimb transfected with human HGF vector, but not control vector at 4 days after transfection (Figure 1b , P Ͻ 0.01). In contrast, human HGF could not be detected in plasma at 3 days, 1, 2 and 4 weeks after transfection. Following an increase in human HGF concentration, injection of human HGF vector into the ischemic hindlimb resulted in a significant increase in blood flow from 3 weeks after transfection to 5 weeks after transfection (P Ͻ 0.01), as shown in Figure 2a increase in blood flow was much greater in rats transfected with 500 g DNA than in those administered 25 or 50 g recombinant HGF at 5 weeks after transfection (P Ͻ 0.01, Figure 4 ). These results demonstrate that angiogenesis induced by gene transfer of HGF would be beneficial as compared with single intra-arterial administration of rHGF.
Angiogenesis induced by intramuscular injection of 'naked' human HGF plasmid in rabbit ischemia model Given the successful therapeutic angiogenesis using 'naked' human HGF plasmid in the rat ischemia model, the feasibility of gene therapy was also examined in a rabbit hindlimb ischemia model as a preclinical study for human gene therapy. Therefore, naked human HGF plasmid was intramuscularly injected into the ischemic hindlimb of rabbits in which the femoral artery was excised to induce unilateral hindlimb ischemia. There was no significant difference in body weight between rabbits treated with HGF plasmid and control vector on day 45 after surgery (data not shown). Similar to rat model, human immunoreactive HGF was observed in rabbits trasnfected with human HGF vector, but not control vector, at 4 days after transfection (HGF: 2.08 ± 0.39 ng/g tissue, control: not detected, P Ͻ 0.01). In addition, rabbit endogenous HGF was also increased in the rabbits transfected with human HGF vector as compared with control vector (data not shown), as HGF itself up-regulated endogenous HGF expression. 12 In contrast, human HGF could not be detected in plasma at 3 days, 1, 2 and 4 weeks after transfection. Intramuscular injection of HGF plasmid into the ischemic limb on day 10 after surgery produced significant augmentation of collateral vessel development as assessed by angiography on day 31 and 45 in the ischemia model, in a dose-dependent manner, as shown in Figure 5 (P Ͻ 0.01). Serial angiograms revealed progressive linear extension of collateral arteries from the origin stem artery to the distal point of the reconstituted parent vessel in HGF-treated animals ( Figure 5 ). Of importance, injection of HGF vector also reduced severe necrosis due to ischemia in rabbit muscle, while vehicletreated rabbits demonstrated severe muscle necrosis (data not shown). Consistent with induction of angiogenesis, a significant increase in blood flow as assessed by a Doppler flow wire under basal conditions was observed in rats transfected with HGF plasmid as compared with rats transfected with control vector (Figure 6 , P Ͻ 0.01). Papaverin treatment increased the blood flow both in rats transfected with HGF plasmid and control vector. Even under papaverin treatment, blood flow was significantly increased in rats transfected with HGF vector as compared with control vector (Figure 6 , P Ͻ 0.01). A significant increase in the blood pressure ratio of ischemic limb to normal limb was also observed in rabbits transfected with HGF plasmid as compared with control vector (the blood pressure ratio of ischemic limb to normal limb of rabbits transfected with control vector is 0.67 ± 0.07; Figure 7 , P Ͻ 0.01). Finally, we tested the side-effects of intramuscular transfection of naked HGF plasmid. Expectedly, there was no significant change in hematology or serum chemistry (data not shown).
Discussion
In patients with critical limb ischemia, since there is no pharmacological treatment, amputation, despite its associated morbidity, mortality, and functional implications, 1, 21, 22 is often recommended as a solution to the disabling symptoms, in particular excruciating ischemic rest pain. [22] [23] [24] Indeed, a second major amputation is required in nearly 10% of such patients. Consequently, the need for alternative treatment strategies in patients with critical limb ischemia is compelling. A novel therapeutic strategy using angiogenic growth factors to expedite and/or augment collateral artery development has recently entered the realm of treatment of ischemic diseases. Indeed, the clinical utility of gene therapy using VEGF gene has been recently reported for the treatment of critical limb ischemia and myocardial ischemia.
4-6 The present study raises the possibility of a new strategy, therapeutic angiogenesis using HGF as gene therapy, instead of VEGF, for the treatment of patients with critical limb ischemia. HGF is a mesenchyme-derived pleiotropic factor which regulates cell growth, cell motility, and morphogenesis of various types of cells, and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis. 25, 26 Based on our recent finding that HGF exclusively stimulated the growth of endothelial cells without VSMC replication, we further studied the capability of HGF to stimulate angiogenesis as a means of gene therapy.
Although the feasibility of therapeutic angiogenesis using HGF has been reported in experimental models, 13 none of the reports has examined the potential utility of HGF gene transfer to stimulate angiogenesis. Here, we demonstrated direct in vivo evidence of therapeutic Gene Therapy angiogenesis induced by HGF gene transfer both in rat and rabbit ischemia models. Notably, a single intramuscular injection of naked HGF plasmid was sufficient to induce therapeutic angiogenesis in the rat and rabbit hindlimb ischemia models. Thus, in vivo transfer of HGF gene into the muscle opens up the possibility of local gene therapy for untreatable peripheral arterial disease, although existing methods have many limitations such as low efficiency and/or potential toxicity.
What is the clinical relevance of therapeutic angiogenesis induced by HGF as compared with VEGF? First, HGF may not cause edema as a side-effect, as it does not increase permeability, different from VEGF. Second, cmet has been reported to be up-regulated in response to hypoxia in a myocardial ischemia model, 15 probably enhancing the angiogenic activity of HGF. Third, previous reports showed elevated levels of cell-associated matrix degrading enzymes (MMP-1, etc) and enhanced 
Figure 7 Effect of transfection of human HGF plasmid on percent increase in ratio of blood pressure in ischemic hindlimb to that in (contralateral) non-ischemic hindlimb at 30 days after transfection. Control, rabbit transfected with control vector (2 mg/body); HGF, rabbit transfected with human HGF vector (1 or 2 mg/body). *P Ͻ 0.05, **P Ͻ 0.01 versus control. Control group contains four animals; each HGF group contains three animals.
plasmin-generating ability (uPA) by HGF. [27] [28] [29] Interestingly, uPA activates pro-HGF in vitro, and activation of pro-HGF involves the formation of a stable complex between pro-HGF and uPA, 29 suggesting that the biological effects of HGF can be titrated in vivo by the level of uPA activity. Increased amounts of uPA locally induced by HGF may condition the tissue microenvironment by rendering HGF bioavailable to its target cells. Fourth, HGF has been postulated to promote angiogenesis as a result of a combination of direct effects on endothelial cells and indirect effects, including paracrine up-regulation of VEGF, on VSMC.
14 Fifth, decrease in endogenous vascular HGF may increase the threshold of safety of HGF, as the present and previous studies demonstrated a decrease in endogenous HGF concentration in the ischemic condition. 13, 19 One of the distinguishing features of HGF mentioned above, the fact that the HGF gene encodes a secretary signal sequence, might be exploited as part of a strategy designed to accomplish therapeutic angiogenesis by arterial gene transfer. Previous reports mentioned that site-specific transfection of rabbit ear arteries with a plasmid encoding the gene for human growth hormone, a secreted protein, yields local levels of human growth hormone equivalent to what has been considered to be in the physiologic range, despite that fact that immunohistochemical examination of the transfected tissue disclosed evidence of successful transfection in Ͻ1% of cells in the transfected arterial segment. 30 Thus, gene products that are secreted may have profound biological effects, even when the number of transduced cells remains low. In contrast, for genes such as bFGF that do not encode a secretory signal sequence, transfection of a much larger cell population might be required for that intracellular gene product to express its biological effects. In these cases, a more highly efficient transfection method would be necessary. Since no human HGF could be detected in serum (detection level of human HGF is over 0.1 ng/ml), angiogenesis was due to local produced HGF. Together with no apparent change in serum chemistry in rabbit experiments, intramuscular transfection of naked HGF plasmid is safe and efficient to treat peripheral arterial disease.
Overall, the present studies suggest a novel therapeutic strategy that might reduce the symptoms of critical limb ischemia, utilizing the angiogenic properties of HGF gene transfer. Currently, we plan to start human clinical trials using HGF naked plasmid DNA to treat peripheral arterial disease. In addition, stimulation of new vessel formation by HGF is likely to create new therapeutic options in angiogenesis-dependent conditions such as wound healing, inflammatory diseases, ischemic heart disease, myocardial infarction and peripheral arterial disease.
Materials and methods
Experiment 1: rat hindlimb ischemia model Construction of plasmids: To produce an HGF expression vector, human HGF cDNA (2.2 kb) was inserted into a simple eukaryotic expression plasmid that utilizes the cytomegalovirus (CMV) promoter/enhancer. This promoter/enhancer has been used to express reporter genes in a variety of cell types and can be considered to be constitutive. Downstream from the HGF from cDNA is the SV40 polyadenylation sequence. The vector used as a control was CMV expression vector plasmid, which did not contain HGF cDNA. We obtained luciferase gene expression vector driven by SV40 promoter from a commercial source (Promega, Madison, WI, USA).
In vivo gene transfer using direct intramuscular injection approach: Sprague-Dawley rats (400-500 g; Charles River Breeding Laboratories, Osaka, Japan) were anesthetized with an intraperitoneal injection of sodium pentobarbital (0.1 ml/100 mg). A longitudinal incision was then made, extending inferiorly from the inguinal ligament to a point just proximal to the patella. Through this incision, using surgical loops, the operator dissected free the right femoral artery along its entire length; all branches of the femoral artery, including the inferior epigastric, deep femoral, lateral circumflex, and superficial epigastric arteries, were also dissected free. 19, 31 After dissection of the popliteal and saphenous arteries distally, the external iliac artery and all of the mentioned arteries were ligated with 4-0 silk (Ethicon, Somerville, NJ, USA). Finally, the right femoral artery was completely excised to create the ischemic limb model, from its proximal origin as a branch of the external iliac artery to the point distally where it bifurcates to form the saphenous and popliteal arteries. Excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Excision of the femoral artery 1 cm below the peritoneum created an ischemia model. Consequently, blood flow to the ischemic limb was dependent on collateral vessels developing from the internal iliac artery.
Design 1: 'Naked' human HGF (100, 250 or 500 g/body) or control vector (500 g/body) was carefully injected directly into the right ischemic limb of rats with a 27 G needle (Terumo, Atsugi, Japan) immediately after surgery. Injection volume of plasmid was 100 l. Design 2: In design 2, we administered a single injection of 25 or 50 g recombinant human HGF (rhHGF) locally (intra-arterially into the right ischemic limb) on the day of the operation. The experimental procedure was the same as described above. Animals were administered the first intra-arterial bolus of rhHGF (25 or 50 g/body) or vehicle (0.1% rabbit serum albumin) over 1 min through a cannula positioned in the internal iliac artery of the ischemic limb.
Analysis of luciferase activity: Firefly luciferase activity was measured using a luciferase assay system (PicaGene; Toyo-Inki, Tokyo, Japan). Rats were killed 5 days after transfection of luciferase gene by direct injection of 'naked' plasmid into the hindlimb. Tissue samples (200 mg around injection site) were rapidly frozen in liquid nitrogen, and homogenized in lysis buffer. The tissue lysates were briefly centrifuged (3000 r.p.m., 10 min), and 20 l of supernatant was mixed with 100 l of luciferase assay reagents. Measurement of the luminescent reaction was started 5 s after the addition of sample. Counting lasted for 10 s, and the count in 10 s was used as an index of luciferase activity. 20 Measurement of HGF concentration in hindlimb: To document successful transfection of HGF vector into the hindlimb, we examined the production of human immunoreactive HGF. 12, 32 Four days after transfection, the hindlimb of rats transfected with HGF or control vector were promptly removed without excess fat after perfusion via the cardiac apex with saline, frozen in liquid nitrogen, and then stored at −70°C until use. On the day of extraction, the tissue was thawed at 4°C, weighed, and homogenized by polytron in assay solution. Each specimen was centrifuged at 20 000 g for 30 min at 4°C, to remove the lysate. The concentration of HGF in the hindlimb was determined by enzyme-immunoassay using anti-human HGF antibody, as described previously. 12, 32 Briefly, rabbit anti-rat or anti-human HGF IgG was coated on 96-well plates (Corning, NY, USA) at 4°C for 15 h. After blocking with 3% bovine serum albumin in phosphate-buffered saline (PBS), conditioned medium was added to each well, and the preparation was incubated for 2 h at 25°C. Wells were washed three times with PBS containing 0.025% Tween 20 (PBS-Tween), biotinylated rabbit antiGene Therapy human HGF IgG was added, and the preparation was incubated for 2 h at 25°C. After washing with PBSTween, wells were incubated with horseradish peroxidase-conjugated streptavidin-biotin complex in PBSTween. The enzyme reaction was initiated by adding substrate solution composed of 2.5 mg/ml o-phenylenediamine, 100 mm sodium phosphate, 50 mm citric acid, and 0.015% H 2 O 2 . The enzyme reaction was stopped by adding 1 m H 2 SO 4 , and absorbance at 490 nm was measured. The antibody against human HGF reacts with only human HGF, and not with rat HGF. 32 Rat immunoreactive HGF in the rat hindlimb was also measured by EIA using anti-rat HGF antibody, as the antibody against rat HGF reacts with only rat HGF, and not with human HGF. 32 
Measurement of blood flow by laser Doppler image:
Measurement of blood flow with a laser Doppler imager (LDI) has been previously described. 33, 34 As it was clearly demonstrated that laser Doppler flow velocity correlates well with capillary density, 33, 34 we measured the cardiac blood flow by means of a laser Doppler blood flowmeter (Laser Doppler Imager, Moor Instruments, Cambridge, UK). Indeed, we confirmed that the blood flow measured by LDI was well correlated with capillary density (data not shown). Excess hairs were removed by depilatory cream from the limb before imaging, and rats were placed on a heating plate at 37°C to minimize temperature variation. Consecutive measurements were obtained over the same regions of interest (leg and foot). LDI uses a 12-mW helium-neon laser beam that sequentially scans a 5 × 5 cm surface area with extremely high speed to be able to measure the blood flow in the ischemic hindlimb. The blood flow 1 mm under the surface can be measured. While scanning, blood cells that are in motion shift according to the frequency of projected light, according to the Doppler principle. Upon termination of scanning, a color-coded image representing blood flow distribution is displayed on a monitor. The perfusion signal is subdivided into 14 different intervals, and each interval is displayed in a separate color. Low or no perfusion is displayed as dark blue, whereas the highest perfusion interval is displayed as white. The stored perfusion values behind the color-coded pixels remain available for data analysis. Before measuring, rats were anesthetized, intubated and connected to a respirator. Perfusion analyses were performed sequentially: (1) the ischemic hindlimb transfected with control vector; (2) the ischemic hindlimb transfected with HGF vector. These laser images were quantitatively converted into histograms that represented the amount of blood flow on the x-axis and the number of pixels on the y-axis in the traced area. The average blood flow in each histogram was calculated for evaluation.
Measurement of capillary density: Alkaline phosphatase staining was used as a specific marker of endothelial cells in paraffin-embedded sections, as previously described. 35, 36 To analyze the number of vessels in the right ischemic hindlimb transfected with HGF vector or control vector, rats were killed and the muscle was removed. Three individual sections from the middle of the transfected muscle were analyzed. The number of vessels was counted under a light microscope (magnification, ×100) in a blinded manner. The total number of vessels in each section was summed and expressed as number per section. At least 10 individual sections were evaluated in each muscle. The areas in which the number of vessels was quantified were randomly selected in and around the injected site. The animals were coded so that the analysis was performed without any knowledge of which treatment for each individual animal had received. The reproducibility of the results was assessed. Intra-observer variability was determined from triplicate measurements performed by one observer for all sections. The mean ±s.d. difference among measurements made by the same observer was 1.8 ± 0.2%. Interobserver variability was determined from measurements of 10 randomly selected sections performed by a second observer in addition to the first. The numerical difference between the measurements made by the two observers was 2.1 ± 0.8%. These observers were blinded to other data concerning the rats, as well as to the results of the other observer.
Experiment 2: rabbit hindlimb ischemia model
Rabbit ischemic hindlimb model: The physiological response to transfection of human HGF vector was also investigated in the rabbit ischemic hindlimb model, described in a previous report. 13, 19 Briefly, male New Zealand White rabbits (3.5 to 4.0 kg) (Kitayama Rabes, Kyoto, Japan) were anesthetized with a mixture of xylazine (5 mg/kg, i.p.) and ketamine (50 mg/kg, i.p.). A longitudinal incision was then made, extending inferiorly from the inguinal ligament to a point just proximal to the patella. Through this incision, using surgical loops, the operator dissected free the left femoral artery along its entire length; all branches of the femoral artery, including the inferior epigastric, deep femoral, lateral circumflex, and superficial epigastric arteries, were also dissected free. After dissection of the popliteal and saphenous arteries distally, the external iliac artery and all of the mentioned arteries were ligated with 4-0 silk (Ethicon). Finally, the left femoral artery was completely excised to create the ischemic limb model, from its proximal origin as a branch of the external iliac artery to the point distally where it bifurcates to form the saphenous and popliteal arteries. Excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Excision of the femoral artery 1 cm below the peritoneum created an ischemia model. Consequently, blood flow to the ischemic limb was dependent on collateral vessels developing from the internal iliac artery.
Four separate injections of 250 or 500 g human HGF vector (total 1 or 2 mg) locally (intramuscular into the ischemic limb) were performed. Ten days after surgery (day 10) and after measurement of baseline body weight, as well as baseline noninvasive and invasive measurements of hemodynamic parameters, the animals received an intramuscular injection of human HGF 'naked' plasmid vector or control plasmid lacking HGF gene (2 mg total) through a 27-gauge needle (Terumo) positioned above and below the knee of the ischemic limb, respectively.
Quantitative angiography: The angiographic luminal diameter of the internal iliac artery in the ischemic limb at baseline and after drug infusion was determined on days 0, 21 and 35 by previously described techniques. 13, 14 Briefly, morphometric analysis of collateral vessel development in the ischemic limb was performed in 4-s angiograms recorded after injection of contrast medium into the internal iliac artery. A grid with 20-mm spaces was placed over the angiogram in the region of the medial thigh. The number of contrast-opacified arteries crossing over circles and the total number of lines encompassing the medial thigh area were counted in a blinded fashion. The angiographic score was calculated as the ratio of overlying opacified arteries divided by the total number of lines in the ischemic thigh. This angiographic score reflects vascular density in the medial thigh.
Intra-arterial Doppler guidewire measurement of blood flow: Blood flow was quantified in vivo before selective internal iliac angiography in New Zealand White rabbits using a 0.018-inch Doppler guidewire (Cardiometrics, South San Francisco, CA, USA). 36 The wire was advanced via the 3-F infusion catheter positioned at the origin of the common iliac artery to the proximal segment of the iliac artery supplying the ischemic limb. Maximum APV (average peak velocity) was recorded at rest. APV was recorded after bolus injection of 2 mg papaverine. After completing identical measurements in the normal limb, selective internal iliac angiography was performed as described above.
The angiographic luminal diameter of the internal iliac artery in the ischemic limb and of the external iliac artery in the normal limb were determined using an automated edge-detection system as previously described. 36 The film selected for analysis was scanned with a high resolution video camera; the signal produced by the video camera was digitized and displayed on a video monitor (Laser Scan Image Comm, Santa Clara, CA, USA). Center lines were traced manually for a 10-mm long segment beginning immediately distal to the tip of the Doppler wire. The contents were subsequently detected automatically on the basis of the weighted sum of the first and second derivative functions applied to the digitized brightness information. The vascular diameter was then measured at the site of the Doppler sample volume (5 mm distal to the wire top). Cross-sectional area was calculated assuming a circular lumen. Doppler-derived flow was calculated as previously described. 36 Measurement of blood pressure: Calf blood pressure was measured using a Doppler flow meter. The pulse of the posterior tibial artery was identified using a Doppler probe, and the systolic blood pressure in both limbs was determined using standard techniques. 36 The calf blood pressure ratio was defined for each rabbit as the ratio of systolic pressure of the ischemic limb to that of the normal limb.
Statistical analysis
All values are expressed as mean ± s.e.m. Analysis of variance with subsequent Duncan's test was used to determine the significance of differences in multiple comparisons. Differences with P value less than 0.05 were considered significant.
